Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Pharma Dividend Stocks To Buy in 2024

In this article, we discuss 5 best pharma dividend stocks to buy in 2024. If you want to read our detailed analysis of the pharma sector and its performance, go directly to read 13 Best Pharma Dividend Stocks To Buy in 2024

5. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 76

An American multinational pharmaceutical company, AbbVie Inc. (NYSE:ABBV) focuses on immunology, oncology, neuroscience, virology, and general medicine. On February 15, the company reported a quarterly dividend of $1.55 per share, which was consistent with its previous dividend. Overall, it has raised its dividends for 51 consecutive years, which makes ABBV one of the best dividend stocks in the pharma sector. The stock’s dividend came in at 3.49%, as of March 4.

As of the close of Q4 2023, 76 hedge funds tracked by Insider Monkey owned stakes in AbbVie Inc. (NYSE:ABBV), up from 73 in the previous quarter. These stakes are worth over $3.5 billion in total. Among these hedge funds, Marshall Wace LLP was the company’s leading stakeholder in Q4.

Follow Abbvie Inc. (NYSE:ABBV)

4. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 79

Pfizer Inc. (NYSE:PFE) is a multinational pharmaceutical company that is primarily engaged in the research, development, manufacturing, and marketing of prescription drugs, vaccines, and consumer healthcare products. The company’s dividend growth streak currently stands at 14 years and it offers a quarterly dividend of $0.42 per share. As of March 4, the stock has a dividend yield of 6.49%.

Pfizer Inc. (NYSE:PFE) ended the fourth quarter with 79 hedge fund positions, growing from 73 in the previous quarter, according to Insider Monkey’s database. The stakes owned by these hedge funds have a total value of over $2.2 billion.

Follow Pfizer Inc (NYSE:PFE)

3. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81

Johnson & Johnson (NYSE:JNJ) is next on our list of the best dividend stocks in the pharma sector. The company has been rewarding shareholders with growing dividends for the past 61 years and pays a per-share dividend of $1.19 every quarter. With a dividend yield of 3.00% as of March 4, JNJ is one of the best dividend stocks on our list.

As per Insider Monkey’s database of Q4 2023, 81 hedge funds reported having stakes in Johnson & Johnson (NYSE:JNJ), compared with 84 in the preceding quarter. The total value of these stakes is nearly $4 billion. With more than 6.3 million shares, Fisher Asset Management was the company’s leading stakeholder in Q4.

Follow Johnson & Johnson (NYSE:JNJ)

2. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 98

Merck & Co., Inc. (NYSE:MRK) is an American pharmaceutical company that is dedicated to improving the health and well-being of people and animals worldwide by delivering innovative and effective medical solutions. The company offers a quarterly dividend of $0.77 per share and has a dividend yield of 2.49%, as of March 4. It has raised its dividends for 13 years in a row, which makes MRK one of the best dividend stocks in the pharma sector.

Merck & Co., Inc. (NYSE:MRK) remained popular among elite funds in Q4 2023 as the company ended the quarter with 98 hedge fund positions, up from 85 in the preceding quarter, according to our database. The stakes held by these hedge funds are worth over $7.16 billion in total.

Follow Merck & Co. Inc. (NYSE:MRK)

1. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 102

Eli Lilly and Company (NYSE:LLY) tops our list of the best dividend stocks in the pharma sector. The company has been increasing its payouts for 10 consecutive years and currently pays a quarterly dividend of $1.30 per share. The stock’s dividend yield on March 4 came in at 2.49%.

At the end of December 2023, 102 hedge funds in Insider Monkey’s database reported having stakes in Eli Lilly and Company (NYSE:LLY), the same as in the previous quarter. The collective value of these stakes is over $11.1 billion.

Follow Eli Lilly & Co (NYSE:LLY)

You can also take a look at 16 Best Large-Cap Value Stocks To Invest In in 2024 and 13 Best EV Stocks To Buy in 2024

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.